Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

Labcorp Holdings Inc (NYSE:LH) is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly ...

INDIANAPOLIS, Dec. 16, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas® 6800/8800 systems version 2.0 and software version 2.0.1, following U.S.

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) is actively working with its partners to enhance laboratory testing capacity worldwide to combat the mpox outbreak. Mpox is a viral infection that causes flu-like ...

FRANKFURT — Swiss drugmaker Roche (ROG.S), said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and ...

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.

BERLIN (Reuters) - Roche is actively working to enhance laboratory testing capacity for mpox worldwide, the Swiss pharmaceutical company said on Tuesday. The World Health Organization last week ...

Roche says it's actively working with its partners to enhance mpox laboratory capacity worldwide to develop diagnostic tests to combat the outbreak. The World Health Organization (WHO) last week ...

ZURICH (Reuters) - Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines , it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive ...

ZURICH, July 2 (Reuters) - - Swiss drugmaker Roche Holding AG is buying Constitution Medical Investors (CMI), the U.S. developer of a testing system for blood diseases like anaemia and leukaemia, for ...